A Global Collaboration to Advance Brain Metastasis Research
Duke Cancer Institute
Carey Anders, MD, director of the Duke Center for Brain and Spine Metastasis, has spearheaded the Consortium for Intracranial Metastasis Academic Research, an international, multidisciplinary network of researchers and clinicians.
Read More
Basic Scientists Study mRNA Technology to Develop Promising Treatments
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Amid federal research cuts, experts in the field of basic science at Johns Hopkins Medicine are harnessing the power of mRNA to find new avenues for promising mRNA-based therapies to treat conditions including cancer and autoimmune and genetic diseases.
Read More
At-Home Melanoma Testing: Skin Patch Test Works in Mice
University of Michigan Rogel Cancer Center
Melanoma testing could one day be done at home with a skin patch and test strip with two lines, similar to COVID-19 home tests, according to University of Michigan researchers. Developed with funding from the National Institutes of Health, the new silicone patch with star-shaped microneedles, called the ExoPatch, distinguished melanoma from healthy skin in mice.
Read More
Study Reveals How HPV Reprograms Immune Cells to Help Cancer Grow
USC Norris Comprehensive Cancer Center
The most common cancer-causing strain of human papillomavirus (HPV), HPV16, undermines the body’s defenses by reprogramming immune cells surrounding the tumor, according to new research from the Keck School of Medicine of USC. In mice, blocking this process boosted the ability of experimental treatments for HPV to eliminate cancer cells.
Read More
Immunotherapy Helps Extend Lives of Patients With Rare Skin Cancer
UCLA Jonsson Comprehensive Cancer Center
A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system attack cancer cells, can effectively shrink or eliminate tumors in patients with unresectable advanced desmoplastic melanoma. The study showed that nearly 90 percent of participants experienced significant tumor reduction or complete disappearance after receiving pembrolizumab.
Read More
Researchers Engineer Rare Immune Cells to Create Powerful New Cancer Vaccine
The Tisch Cancer Institute at Mount Sinai
Nina Bhardwaj, MD, PhD, and colleagues have developed a novel method to generate billions of conventional type I dendritic cells, paving the way for off-the-shelf cellular vaccines for many cancer types.
Read More
Genomics-Guided Tool to Inform Treatment of Advanced Kidney Cancers
Roswell Park Comprehensive Cancer Center
A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy – information that helped researchers create a first-of-its-kind tool to guide treatment decisions for advanced kidney cancers.
Read More
Understanding What Makes Some Bladder Cancers Resistant to Chemotherapy
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist chemotherapy and identify better ways to treat those cancers, researchers at Baylor College of Medicine have conducted a detailed molecular analysis of MIBC tumors.
Read More
Vesalius Cell-Mapping Tool Provides Insightful Multi-Layered View of Cancer Behavior
VCU Massey Comprehensive Cancer Center
Researchers at VCU Massey Comprehensive Cancer Center have developed a new computational tool called Vesalius, which could help clinicians understand the complex relationships between cancer cells and their surrounding cells, leading to potential discoveries regarding the development of hard-to-treat cancers.
Read More
Do These Two Cancer Drugs Have What It Takes to Beat Alzheimer's?
UCSF Helen Diller Family Comprehensive Cancer Center
Scientists at UC San Francisco and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in the brain during Alzheimer’s, potentially slowing or even reversing its symptoms.
Read More
Final Clinical Trial Data Reported for Advanced Kidney Cancer Treatment
Vanderbilt-Ingram Cancer Center
A two-drug combination for advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a new study that reports final clinical data and biomarker analyses from a trial that compared the drug combination pembrolizumab plus axitinib versus the single drug sunitinib for previously untreated advanced clear cell renal cell carcinoma.
Read More
This Artificial Sweetener Could Make Cancer Treatment Less Effective
UPMC Hillman Cancer Center
Sucralose is a popular sugar substitute for people who are cutting calories or managing blood sugar levels, but new research by the University of Pittsburgh and UPMC Hillman Cancer Center suggests that the artificial sweetener may not be the best choice for patients undergoing cancer immunotherapy.
Read More
FDA Clears New DMG Treatment: What It Means for a Deadly Pediatric Brain Tumor
University of Michigan Rogel Cancer Center
A class of diffuse midline gliomas (DMG), aggressive tumors that begin in the brain or spinal cord, contains a mutation called H3K27M, which usually occurs in pediatric patients. It's always fatal, and patients typically live for nine to 15 months after diagnosis. There’s new hope, though, as the U.S. Food and Drug Administration has approved ONC201 (dordaviprone) to treat recurrent H3K27M-mutant diffuse glioma.
Read More
Study Identifies Molecular Pathway That Drives Advanced Prostate Cancer
UK Markey Cancer Center
UK Markey Cancer Center researchers have identified a cellular pathway that fuels the progression of aggressive, drug-resistant prostate cancer. The findings of the study could lead to new treatment approaches for patients whose cancers no longer respond to hormone therapy.
Read More
Trial Leads to FDA Approval of Drug for Rare, Deadly Blood Cancer
Stanford Cancer Institute
Nearly three-quarters of people with a subtype of a rare form of deadly blood cancer saw their cancers become undetectable—as measured by imaging, laboratory tests and examination of biopsy specimens—after treatment with a drug called pemigatinib in a Phase II, multicenter, international trial run by Stanford Medicine.
Read More
A Microbial DNA Signature Differentiates Two Types of Cancer in the Liver
UC San Diego Moores Cancer Center
Researchers at University of California San Diego have identified a microbial DNA signature in blood plasma that reliably differentiates primary liver cancer from colorectal cancer that has spread to the liver (metastatic colorectal cancer).
Read More
AI Reveals How Protein Modifications Link Mutations to Disease
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
Researchers at Baylor College of Medicine have developed an artificial intelligence (AI) model that reveals how protein modifications link genetic mutations to disease. The method, called DeepMVP, significantly outperforms previously published models and has implications for the development of novel therapeutics.
Read More
New Research Uncovers Gene Impacts of PFAS Exposure in Firefighters
The University of Arizona Cancer Center
Researchers at the University of Arizona found that certain kinds of long-lasting chemicals firefighters are exposed to may affect the activity of genes linked to cancer and other diseases. The study is among the first to connect common industrial chemicals called PFAS to changes in microRNAs, or miRNAs, which are molecules that help control gene expression.
Read More
Roswell Park Leads Largest-Ever Genomic Study of Triple-Negative Breast Cancer in African American Women
Roswell Park Comprehensive Cancer Center
Triple-negative breast cancer disproportionately affects African American women – but until now, they were underrepresented in genomic studies aimed at identifying the genetic mutations driving the disease. A landmark study led by researchers at Roswell Park Comprehensive Cancer Center and collaborating institutions fills that knowledge gap.
Read More
Study Shows Childhood Cancer Survivors Face New Health Problems Later in Life
City of Hope Comprehensive Cancer Center
Researchers at City of Hope® have found that some survivors of childhood cancer are more at risk for serious health issues as they grow older, including new cancers and chronic conditions like heart disease. While a cause for concern, the findings also point to a silver lining: the ailments are potentially manageable if caught early and treated.
Read More
Triple Threat CAR T-Cell Therapy Clinical Trial Debuts
The University of Kansas Cancer Center
There are now seven FDA-approved CAR T-cell treatments, and they have produced dramatic results. But CAR T-cell therapy does not work for everyone. Now, a new type of CAR T-cell therapy dubbed Triple Threat, currently under evaluation via a Phase I, first-in-human clinical trial initiated by investigators at KU Cancer Center, tests a CAR T-cell therapy that triples the number of molecular targets.
Read More
AI Tool Speeds Acute Myeloid Leukemia Diagnosis
University of Florida Health Cancer Center
University of Florida Health researchers has developed a digital tool that uses artificial intelligence to accelerate the diagnosis of acute leukemias. The team developed the Acute Leukemia Methylome Atlas, or ALMA, by mapping specific tags in DNA referred to as methylation patterns across 3,300 leukemia samples. ALMA can match patients to 27 leukemia subtypes as defined by the World Health Organization.
Read More
Cancer Vaccine Elicits Strong Immune Response in Pancreatic, Colorectal Cancer
UCLA Jonsson Comprehensive Cancer Center
A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer, according to a study led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Read More
New Treatment Eliminates Bladder Cancer in 82 Percent of Trial Patients
USC Norris Comprehensive Cancer Center
A new drug-releasing system, TAR-200, eliminated tumors in 82 percent of patients in a Phase II clinical trials for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment. In the majority of cases, the cancer disappeared after only three months of treatment, and almost half the patients were cancer-free a year later.
Read More
Drug Combination May Provide Effective New Treatment for Kidney Cancer Subtypes
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
The OSUCCC – James played a key role in a National Cancer Institute study that showed the efficacy of combining bevacizumab and erlotinib in 43 patients with advanced hereditary leiomyomatosis and renal cell cancer-associated papillary renal cell carcinoma, and in 40 patients with sporadic (non-hereditary) papillary renal cell carcinoma.
Read More
Some Breast Tumors Tunnel Into Fat to Fuel Up. Can We Stop Them?
UCSF Helen Diller Family Comprehensive Cancer Center
A team of researchers at UC San Francisco have uncovered a mechanism by which triple-negative breast cancer tumors fuel growth by drawing energy from nearby fat cells. The study points to potential new treatment options.
Read More
Study Shows How Cells Sense Nutrients and Initiate Growth
Stanford Cancer Institute
Determining how molecular mechanisms become dysregulated is essential in shaping our understanding of cancer. To initiate growth, cells tap into the nutrient supply inside and outside of the cell, but it’s unclear how they detect if they have enough nutrients for growth. A Stanford Cancer Institute study sheds light on how cells sense nutrient availability and use that information to activate or inhibit growth.
Read More
Back to News From the Centers
New Thyroid Cancer Center Announced
Duke Cancer Institute
Duke Cancer Institute has launched the Thyroid Cancer Center, a multidisciplinary hub dedicated to delivering the highest level of care for patients with thyroid disease.
Read More
Expanding Access to CAR T-Cell Therapy
The University of Kansas Cancer Center
In 2022, Nausheen Ahmed, MD, and her team published a study showing clear issues in who could access CAR T-cell therapy. They followed up with two more studies in 2024, one focusing on myeloma and the other on lymphoma.
Read More
TIL Therapy Provided for Advanced Melanoma
VCU Massey Comprehensive Cancer Center
VCU Massey Comprehensive Cancer Center provides tumor-infiltrating lymphocyte (TIL) therapy for advanced stage melanoma patients. This one-time treatment option—the first cellular therapy to be FDA-approved for solid tumors—may also be commonly referred to as "adoptive cell therapy," "Amtagvi," or "lifileucel."
Read More
Design and Management of Cancer Clinical Trials Course Starts September 5
Sylvester Comprehensive Cancer Center, University of Miami
This course was designed to provide physicians and others involved in developing and managing clinical trials with key information to foster better clinical trial design, advance a program of clinical research, and ultimately improve patient care. Participants will learn basic research concepts and principles that underlie the design and day-to-day conduct of cancer clinical trials.
Register Here
Proton Therapy Center Expansion to Boost Patient Capacity Across Mountain West
Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute is expanding its Senator Orrin G. Hatch Proton Therapy Center, doubling treatment capacity and increasing access for patients in Utah, Idaho, Montana, Nevada, and Wyoming.
Read More
Back to News From the Centers